Bleeding Disorder News and Research

RSS

Novel therapeutic approaches for various forms of thrombocytopenia

Four studies that highlight significant advances in treatment and survival outcomes for patients with various forms of thrombocytopenia, a group of bleeding disorders characterized by a low number of platelets in the blood, were presented December 6 during the 50th Annual Meeting of the American Society of Hematology in San Francisco, CA.

8 Dec 2008

New clinical study will help doctors assess abnormal bleeding

How do you know if you bleed normally? Scientists at The Rockefeller University Hospital's Center for Clinical and Translational Science (CCTS) aim to answer that question more definitively with the launch of an assessment tool designed to help physicians and researchers more accurately determine what is inside and outside the normal range of bleeding symptoms.

3 Nov 2008

FDA licenses Kogenate FS to prevent joint damage in children with hemophilia A

The U.S. Food and Drug Administration has approved a new use for the blood product Kogenate FS to reduce the frequency of bleeding episodes and prevent joint damage in children with the most severe form of hemophilia.

12 Oct 2008

Outbreak of mystery disease kills four in South Africa

A mystery flu-like disease which has killed four people in South Africa is causing concern because the disease appears to be highly contagious and health authorities are urging people not to panic.

7 Oct 2008

Best use of drug-eluting stents: When should they be avoided?

Compared with bare metal stents, drug-eluting stents substantially reduce the risk of angiographic and clinical recurrence but do not affect mortality or the short term or long term risk of myocardial infarction.

31 Aug 2008

CSL Behring study shows extended half-life recombinant VIIa leads to longer biologic activity

CSL Behring today presented results of a pre-clinical study that not only demonstrates the feasibility of genetically fusing factor VIIa to human albumin, but that this therapeutic protein with a prolonged half-life can lead to a longer biologic effect.

3 Jun 2008

Chemically modified protein may help people with hard-to-treat hemophilia

Pathologists at The University of Texas Health Science Center at Houston have developed a chemically modified protein that may help people with a hard-to-treat form of a genetic bleeding disorder known as Hemophilia A. The discovery and the results of pre-clinical tests appear in the May 2 issue of the Journal of Biological Chemistry.

19 May 2008

Guidelines for von Willebrand disease diagnosis and management

The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health today issued the first clinical guidelines in the United States for the diagnosis and management of von Willebrand Disease (VWD), the most common inherited bleeding disorder.

4 Mar 2008

New guidelines for von Willebrand disease

The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, has issued the first clinical guidelines in the United States for the diagnosis and management of von Willebrand Disease (VWD), the most common inherited bleeding disorder.

1 Mar 2008

Omega-3 fatty acids for depression - new trial

Researchers at Cedars-Sinai Medical Center's Department of Psychiatry and Behavioral Neurosciences are seeking participants for a clinical trial examining whether two polyunsaturated Omega-3 fatty acids are effective treatments for depression.

18 Dec 2007

FDA approves change in storage conditions for Humate-P

The U.S. Food and Drug Administration has approved a change in the storage conditions for Humate-P, a treatment for bleeding in certain patients with hemophilia A or von Willebrand Disease (vWD).

22 Oct 2007

Prophylaxis effective at preventing joint bleeds and preserving joint function and structure in young boys with hemophilia A

According to a new landmark study published in The New England Journal of Medicine, infusions of clotting factor VIII used preventively can significantly reduce the risk of developing joint damage associated with joint bleeding in young children with hemophilia A.

9 Aug 2007

FDA approves Norditropin for short stature in children with Noonan syndrome

Novo Nordisk has announced that Norditropin (somatropin[rDNA origin] injection) received U.S. Food and Drug Administration (FDA) approval for the treatment of short stature in children with Noonan syndrome.

3 Jun 2007

FDA approves new treatment for von Willebrand disease

The U.S. Food and Drug Administration (FDA) has approved Humate-P (Antihemophilic Factor/von Willebrand Factor Complex) for the prevention of excessive bleeding during and after surgery in certain patients with mild to moderate and severe von Willebrand disease (vWD).

30 Apr 2007

Apolipoprotein C1 protein linked to elevated BMI in people of American Indian and Mexican ancestry

University of Minnesota researchers have discovered a variant of a common blood protein, apolipoprotein C1, in people of American Indian and Mexican ancestry that is linked to elevated body mass index (BMI), obesity and Type 2 diabetes.

22 Feb 2007

Alphanate approved to treat Von Willebrand disease

The U.S. Food and Drug Administration (FDA) has announced the approval of Antihemophilic Factor/von Willebrand Factor Complex (Human), Alphanate.

4 Feb 2007

Potential permanent genetic cure for hemophilia A

A discovery by Medical College of Wisconsin and BloodCenter of Wisconsin researchers in Milwaukee may be a key to a permanent genetic cure for hemophilia A patients, including a subset who do not respond to conventional blood transfusions.

3 Jul 2006

Costly IVIg could be replaced with synthetic blood product

Patients suffering from a life-threatening bleeding disorder are closer to having access to a more effective treatment.

1 Jun 2006

Ancient DNA helps unearth potential hemophilia therapy

A cut can be life-threatening for people with hemophilia, whose bodies don't produce enough of a protein that prevents prolonged bleeding.

1 Mar 2006

Emerging infectious agents pose new risks for people with bleeding disorders

An international team of scientists, including a hematologist from Thomas Jefferson University in Philadelphia, has concluded that people with bleeding disorders such as hemophilia remain at risk from emerging infectious agents in plasma and blood transfusions. For this reason, recombinant therapies, that is, those produced in the laboratory, must always be an option

16 Feb 2006